As such, Black patients might also have worse outcomes due to underlying health disparities and access to care that may have led to delays in diagnosis and treatment compared to groups of patients who have more access to screening, such as skin examinations.39 This may explain why White patients continue to demonstrate better overall survival than non-White groups across different melanoma subtypes, irrespective of TERT promoter mutations.34,36,40. The gene discussed is TERT; the disease is melanoma.